SCHEMBL19629908

SCHEMBL19629908

COC1(CN(Cc2ccccc2)Cc2ccccc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.43
TSHR P16473 3/20 0.42
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 2/20 0.41
OPRM1 P35372 3/20 0.40
OPRL1 P41146 3/20 0.40
AOC3 Q16853 1/20 0.38
CYP2C19 P33261 2/20 0.38
CALM1 P0DP23 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
LMNA P02545 2/20 0.37
USP2 O75604 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
PYCR1 P32322 1/20 0.37
KDM4E B2RXH2 1/20 0.37
BCHE P06276 1/20 0.36
BLM P54132 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20740355 0.83 TAAR1 (0.44) OPRM1AOC3CYP2C19CYP3A4BCHE
SCHEMBL15270849 0.83 CALM1 (0.42) CNR2TSHRMAPK1ALDH1A1OPRM1
SCHEMBL16037664 0.82 CNR2 (0.38) CNR2TSHRMAPK1ALDH1A1OPRM1
SCHEMBL23675665 0.77 TSHR (0.43) TSHRALDH1A1OPRM1OPRL1LMNA
SCHEMBL22647553 0.75 CNR2 (0.35) CNR2TSHRMAPK1ALDH1A1OPRM1
SCHEMBL17700462 0.73 ALDH1A1 (0.41) CNR2TSHRMAPK1ALDH1A1OPRM1
SCHEMBL17700363 0.72 ALDH1A1 (0.45) CNR2TSHRALDH1A1OPRM1OPRL1
SCHEMBL13664806 0.69 CA2 (0.40) CNR2TSHRALDH1A1OPRM1OPRL1
SCHEMBL3029785 0.69 TSHR (0.50) CNR2TSHRMAPK1ALDH1A1AOC3
SCHEMBL6644202 0.69 TSHR (0.50) CNR2TSHRMAPK1ALDH1A1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466821-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2025-11-11 US disclosed
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-06-06 US disclosed
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-06-06 US disclosed
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-02-16 US disclosed
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-02-16 US disclosed
US-11267825-B2 Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) AICURIS GMBH & CO. KG (DE) 2022-03-08 US disclosed
US-11072610-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2021-07-27 US disclosed
US-11072610-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2021-07-27 US disclosed
EP-3849979-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS Novartis AG (CH) 2021-07-21 EP disclosed
CN-112996789-A Antiviral pyridopyrazinedione compounds 诺华股份有限公司 2021-06-18 CN disclosed
US-20200354379-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2020-11-12 US disclosed
US-20200354379-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2020-11-12 US disclosed
EP-3704127-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2020-09-09 EP disclosed
WO-2020053654-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS AG (CH) 2020-03-19 WO disclosed
US-20200079772-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS AG (CH) 2020-03-12 US disclosed
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-09-12 US disclosed
EP-3444250-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2019-02-20 EP disclosed
WO-2017198149-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF 江苏豪森药业集团有限公司 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276451-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF FGFR4, FGFR1, FGFR2 CNR2 4205/4885TSHR 3437/4885MAPK1 365/4885
US-11667631-B2 FGFR4 inhibitor, preparation method therefor, and applications thereof FGFR4, FGFR1, FGFR2 CNR2 4205/4885TSHR 3437/4885MAPK1 365/4885
US-12466821-B2 Antiviral pyridopyrazinedione compounds ZC3HAV1, IL5, TYMP CNR2 2593/4885TSHR 4291/4885MAPK1 1282/4885
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS ZC3HAV1, IL5, TYMP CNR2 2593/4885TSHR 4291/4885MAPK1 1282/4885
US-11072610-B2 Antiviral pyridopyrazinedione compounds ZC3HAV1, IL5, TYMP CNR2 2593/4885TSHR 4291/4885MAPK1 1282/4885
US-20200079772-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS ZC3HAV1, IL5, TYMP CNR2 2593/4885TSHR 4291/4885MAPK1 1282/4885
US-20200354379-A1 NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) HCCS, CDK2, BRD4 CNR2 1286/4885TSHR 3299/4885MAPK1 2287/4885
US-11267825-B2 Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) HCCS, BRD4, IDO2 CNR2 1413/4885TSHR 3258/4885MAPK1 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.